Business & Finance

DiagnoCure announces fiscal 2006 fourth quarter and year-end results, focused strategic direction

Published in Health Business Week, January 12th, 2007

DiagnoCure Inc. (CUR), a leading developer of molecular diagnostics for the detection and management of cancer, announced a net loss from continuing operations of $1,718,318 or $0.05 per share for the quarter ending October 31, 2006, and a net loss from continuing operations of $6,491,586 or $0.19 per share for the fiscal year.

The company reported that progress continues on the market development of Gen-Probe's test for prostate cancer based on DiagnoCure's PCA3 gene. The test, which scientists believe will be more accurate than existing tests for prostate cancer, received European CE mark status and was launched in Europe in November. "Our partner, Gen-Probe (GPRO),...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2007-01-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry